Atezolizumab regimen active in NSCLC with untreated brain metastases

atezolizumab regimen active in nsclc with untreated brain metastases

Sumary of Atezolizumab regimen active in NSCLC with untreated brain metastases:

  • September 10, 2021 2 min read Source/Disclosures Published by: Source: Nadal E, et al.
  • Nadal and colleagues conducted their study to assess the efficacy and safety of atezolizumab (Tecentriq, Genentech/Roche), an anti-PD-L1 monoclonal antibody, for patients with advanced NSCLC and untreated, asymptomatic brain metastases.
  • Secondary endpoints included response rate, duration of response, OS, quality of life, neurocognitive function and time to brain radiotherapy.
  • The most common adverse events included fatigue (any grade, 60%;
  • The most common immune-related adverse events included skin rash (any grade, 20%;
  • Three patients experienced grade four treatment-related adverse events (thrombocytopenia, neutropenia and hallucinations).

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close